GetTopicDetailResponse(id=81b451265b, topicName=course, introduction=course, content=null, image=null, comments=4, allHits=818, url=https://h5.medsci.cn/topic?id=5126, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=72102, tagList=[TagDto(tagId=72102, tagName=course)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1783664, encodeId=50021e83664ea, content=<a href='/topic/show?id=81b451265b' target=_blank style='color:#2F92EE;'>#course#</a>, objectTitle=EUR J Cancer：治療結(jié)直腸癌患者的III期RECOURSE臨床試驗(yàn)的亞組中 trifluridine / tipiracil（TAS-102）與安慰劑, objectType=article, longId=124746, objectId=df36124e4632, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df36124e4632, replyNumber=0, likeNumber=105, createdTime=2018-07-20, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df36124e4632, moduleTitle=EUR J Cancer：治療結(jié)直腸癌患者的III期RECOURSE臨床試驗(yàn)的亞組中 trifluridine / tipiracil（TAS-102）與安慰劑, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=df36124e4632)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783663, encodeId=e2d51e83663c5, content=<a href='/topic/show?id=81b451265b' target=_blank style='color:#2F92EE;'>#course#</a>, objectTitle=RECOURSE試驗(yàn)III期：TAS-102對比安慰劑治療已給予更佳支持治療且能耐受標(biāo)準(zhǔn)化療的mCRC患者, objectType=article, longId=43695, objectId=811c4369574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=811c4369574, replyNumber=0, likeNumber=91, createdTime=2015-01-14, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=811c4369574, moduleTitle=RECOURSE試驗(yàn)III期：TAS-102對比安慰劑治療已給予更佳支持治療且能耐受標(biāo)準(zhǔn)化療的mCRC患者, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=811c4369574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783662, encodeId=44cd1e8366277, content=<a href='/topic/show?id=81b451265b' target=_blank style='color:#2F92EE;'>#course#</a>, objectTitle=Instr Course Lect：轉(zhuǎn)子間骨折的10個手術(shù)技巧, objectType=article, longId=27619, objectId=89f82e61993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89f82e61993, replyNumber=0, likeNumber=81, createdTime=2014-01-30, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89f82e61993, moduleTitle=Instr Course Lect：轉(zhuǎn)子間骨折的10個手術(shù)技巧, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=89f82e61993)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1783661, encodeId=1acc1e8366189, content=<a href='/topic/show?id=81b451265b' target=_blank style='color:#2F92EE;'>#course#</a>, objectTitle=清華北大交大相繼加入全球在線課程聯(lián)盟Edx和Coursera, objectType=article, longId=21038, objectId=a08f210388a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a08f210388a, replyNumber=0, likeNumber=98, createdTime=2013-08-13, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a08f210388a, moduleTitle=清華北大交大相繼加入全球在線課程聯(lián)盟Edx和Coursera, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=a08f210388a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
